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Long-term course and mechanisms of progression of renal
disease in hemolytic uremic syndrome
HORATIO A. REPETTO
Service of Pediatrics, Hospital Nacional Prof. Dr. Alejandro Posadas, Argentina
Long-term course and mechanisms of progression of renal dis-
ease in hemolytic uremic syndrome. In the classic form of
hemolytic uremic syndrome associated with toxins of gram-
negative enterobacteria, mortality in the acute stage has been
lower than 5% since 1978 (data from the Nephrology Com-
mittee, Argentine Society of Pediatrics). Children usually die
because of severe involvement of the central nervous system,
intestine, or myocardium and its complications, or because of in-
tercurrent infection. Treatment in this phase is supportive, and
efforts should be put into prevention of infection by Shiga-like
toxin-producing enterohemorrhagic Escherichia coli.
Of the 95% who survive, approximately one third is at risk for
having chronic sequelae. Motor, sensory, or intellectual deficits,
intestinal strictures, myocardial infarctions, or diabetes are in-
frequent. The more-frequent chronic renal lesion is character-
ized by the hyperfunction of nephrons remaining after the acute
necrotizing lesion, which leads to progressive scarring, and not
by persistence or recurrence of the microangiopathic process.
Three courses of progression to end-stage renal failure have
been described. Children with most severe forms do not recover
from acute renal failure and enter directly into a dialysis and
transplantation program. A second group recovers renal func-
tion partially, with persistent proteinuria and frequently hyper-
tension; progression to end-stage renal failure occurs in 2 to 5
years. The third group may recover normal serum creatinine
and creatinine clearance, with persistent proteinuria. They are
at risk of progressing to chronic renal failure and end-stage re-
nal disease after more than 5 years, and sometimes as late as 20
years, after the acute disease. Treatment should aim at prevent-
ing the mechanisms associated with progressive renal scarring.
Transplantation is indicated in this form of hemolytic uremic
syndrome, because there is little, if any, risk of recurrence, and
the prognosis is similar to that of transplantation for other dis-
eases.
Resumen
En la forma cla´sica del Sı´ndrome Hemolı´tico Ure´mico
(SHU) asociado a toxinas de enterobacterias gram negativas,
la mortalidad en la fase aguda ha sido menor al 5% desde 1978.
Las causas de muerte se deben a complicaciones neurolo´gicas,
intestinales, cardiacas o a infecciones intercurrentes. Del 95%
restante, aproximadamente un 30% esta´n en riesgo de desar-
rollar secuelas cro´nicas. La lesio´n renal ma´s frecuente se debe
a hiperfiltracio´n de las nefronas remanentes, lo cual conduce
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a fibrosis progresiva, y no a la persistencia o recurrencia de la
enfermedad microangiopa´tica.
Su curso clı´nico puede seguir tres caminos. En el primero,
los nin˜os con las formas ma´s severas nunca se recuperan de la
fase aguda y pasan directamente a dia´lisis y trasplante; un se-
gundo grupo recupera parcialmente la funcio´n renal, presenta
albuminuria persistente e hipertensio´n y desarrolla insuficiencia
renal cro´nica en un lapso de 2 a 5 an˜os. Finalmente, en un tercer
grupo, las cifras de creatinina se´rica y la depuracio´n de creatin-
ina regresan a la normalidad, con albuminuria persistente y se
encuentran en riesgo de desarrollar insuficiencia renal cro´nica
despue´s de cinco, o en algunos casos, hasta veinte an˜os despue´s
de la fase aguda. El tratamiento se debe orientar a prevenir los
mecanismos de la progresio´n del dan˜o renal. Se requieren de
estudios a largo plazo para evaluar estos tratamientos, ası´ como
el mejor momento de utilizarlos. El trasplante renal esta´ indi-
cado en esta forma de SHU, ya que el riesgo de recurrencia es
mı´nimo y la supervivencia del injerto es similar al observado en
otras patologı´as.
Hemolytic uremic syndrome (HUS) is a systemic
thrombotic microangiopathy (TMA) caused by differ-
ent etiologies and mechanisms (Table 1), which results in
endothelial lesions leading to thrombosis of the microcir-
culation in most organs. The most frequent cause in pe-
diatrics is a lesion due to the effect of toxins of a group of
enterobacteria, enterohemorrhagic Escherichia coli, usu-
ally presenting with diarrhea (D+, epidemic, entero-
pathic, typical). Studies of large groups of patients have
shown that it behaves as a “one-shot disease,” caus-
ing necrotic lesions in the kidney, intestine, central ner-
vous system (CNS), pancreas, myocardium, and liver.
Hemolytic anemia, on the other hand, resolves after the
acute stage.
POST-ACUTE COURSE
More than 95% of children recover from the acute
phase [1]. Lesions in organs other than the kidney de-
pend on the magnitude of the acute insult, because typi-
cally the disease mechanism is not persistent or recurrent.
CNS sequelae are infrequent [2, 3], and chronic lesions in
the colon, pancreas, and liver are reported occasionally
[3, 4]. Residual kidney involvement, on the other hand,
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Table 1. Hemolytic uremic syndrome: Clinical entities
Group Causes Denomination
Associate to infections Bacterial cytotoxin (E. coli, Shigella,
Salmonella), pneumococal neuraminidase,
viral, microtatobiote, etc.
Epidemic, “classical” D+, enteropathic
Idiopathic Related to primary endothelial dysfunction? Hereditary, (autosomic recessive,
autosomic dominant), sporadic, atypical
Genetic Complement factor H
von Willebrand factor protease
Recurrent TTP
Immunologic von Willebrand factor protease Ab
Associated with systemic diseases or other
precipitating factors
Cancer, pregnancy, malignant hypertension,
transplant rejection, glomerulopathies
Toxics Cyclosporine, tacrolimus, mitomycin,
radiation
TTP, thrombotic thrombocytopenic purpura.
is seen in about one third of those who recover from the
acute phase.
FOLLOW-UP OF THE KIDNEY LESION
After more than 1 year of follow-up, a patient with nor-
mal serum creatinine (SCr) and/or creatinine clearance
(Ccr), normal blood pressure, and normal urinalysis is
considered “cured.” Yet some studies have documented
the presence of microalbuminuria or lack of “functional
reserve” after protein loads. This group accounts for 49%
of a cohort of 208 children at 1 year after the acute stage.
At 3 years’ follow-up, 62% (128) were still in this group,
which shows that some patients were still recovering from
the acute insult after the first year [5]. In 118 patients fol-
lowed up for more than 10 years, the proportion did not
change [6]. Some patients presented normal SCr or Ccr
and persistent proteinuria with or without hypertension.
Most of them, followed for some time without treatment,
showed deterioration of glomerular filtration rate. This
group was 6% at 1 year, 14% at 3 years, and 18% after
more than 10 years of follow-up. A third group presented
decreased Ccr or increased SCr, with different degrees
of persistent proteinuria (which may be in the nephrotic
range) and frequently hypertension. At 1 year, 45% of
the children belonged to this group, decreasing to 24%
at 3 years and 19% after more than 10 years. (Fig. 1)
Within this group, some patients were in end-stage re-
nal failure (ESRF). A small proportion of them never
recovered completely from acute renal failure, develop-
ing ESRF an average of 4 years after the acute illness.
The majority recovered normal SCr, arriving at ESRF
after an average of 9.8 years, and as long as 22 years of
follow-up [5].
Studies from around the world have shown a similar
proportion after the same course, when the description
of the acute episode shows that most of the patients had
a form of HUS associated with Shiga-like toxin (SLT)
[7–10]. Although the most recent metaanalysis used a
different schema, the proportion of those “cured” was
similar [11].
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Fig. 1. Renal status at 1, 3, and >10 years of follow-up after acute HUS.
MECHANISM OF PROGRESSION
Several years ago, we suggested that patients with HUS
whose renal function deteriorated after a period of nor-
mal function (as measured by SCr or Ccr) did so because
of hyperfunction of the remaining nephrons—the dis-
ease being a clinical model of the classical mechanism
of progression of chronic renal failure [12]. Three lines
of research have registered data compatible with this hy-
pothesis. In our study, 4 of 12 patients with normal Ccr
many years after the acute stage were unable to increase
their inulin clearance when challenged with protein loads.
One possible interpretation is that they were using their
“functional reserve” in the presence of a reduced nephron
mass. The maximal filtration capacity after the protein
load in the 12 patients was 84.9 mL/min/1.73m2, signif-
icantly lower than that in the normal controls (154.7
mL/min/1.73m2) (P < 0.025) [12] (Fig. 2).
The second evidence for hyperfiltration injury was the
demonstration that some children had microalbuminuria
with normal clinical and laboratory findings years after
an acute episode of HUS. The authors speculated that
it could be a predictor of progressive lesions, similar to
other renal diseases [13].
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Fig. 2. Mean CIN before and 3 hours after a protein load in patients
with HUS at follow-up. CIN, inulin clearance.
A third line of inquiry was reported in the study of
sequential biopsies in which the proportion of glomeruli
involved in the acute insult was the same as that of scarred
glomeruli later [14]. Histologic changes in patients with
chronic renal sequelae show focal and segmental sclero-
sis and mesangial expansion in the glomeruli [15]. These
observations also suggest the mechanism of residual hy-
perfunction as the cause of progressive scarring and loss
of renal function.
In this respect, the finding that acute stage HUS is
associated with increased risk of chronic disease sug-
gests a more severe acute systemic microangiopathic pro-
cess. The presence of anuria, its duration, and the need
and duration of dialysis are variables reported to predict
long-term outcome [6–10]. Persistent hypertension after
the recovery of diuresis also points to an increased risk
of chronic lesions [5]. Several extrarenal manifestations,
probably reflecting a more severe diffuse microangio-
pathic process, such as marked CNS [8, 10] and intestinal
symptoms [15], are also associated with a poor long-term
prognosis. The importance of age at onset is controver-
sial. Although a recent report suggests that older chil-
dren might have a poorer prognosis [17], other authors
conclude that there is no difference in outcome [18].
MANAGEMENT OF CHRONIC RENAL DISEASE
IN HUS
Treatment in the acute stage of SLT-associated dis-
ease is supportive, but greater efforts should be put into
prevention. The high incidence in Argentina is due to
the large numbers of cattle colonized with enterohem-
orrhagic Escherichia coli that produce SLT-2, which has
been shown to be more toxic. Control of production, dis-
tribution, and expenditure of meat and other cattle prod-
Table 2. Causes leading to terminal renal failure in a cohort of 200
consecutive children who had received transplants
Diseases Number of patients %
Uropathy 81 40
Glomerulonephropathy 39 19.5
Hemolytic uremic syndrome 31 15.5
Primary nephritic syndrome with
focal and segmental
glomerulosclerosis
21 11
Hypodysplasia 11 5.5
Interstitial nephropathy 7 3.5
Neurogenic bladder 5 2.5
Polycystic kidney 3 1.5
Cystinosis 2 1
Total 200 100
ucts, public education on the handling and processing of
meals, and development of vaccines are actions that could
decrease the frequency of this endemic disease.
Knowing the risks for chronic sequelae, close follow-up
is required. Frequent controls of blood pressure and pres-
ence of proteinuria are mandatory. Although evidence
for controlling the mechanisms of progression by inter-
fering with the activity of angiotensin II is circumstan-
tial and mostly extrapolated from other renal diseases by
speculating the existence of a similar mechanism, con-
trol of hypertension to average or low-normal values,
and treatment of proteinuria persisting for 6 months after
the acute period with ACE inhibitors is recommended.
One prospective, controlled, multicenter study aiming to
demonstrate the effect of enalapril and losartan (an an-
giotensin II receptor blocker) on proteinuria is being per-
formed in Argentina. Also, studies on the effect of these
drugs on microalbuminuria detected in the late course of
HUS should be planned.
HUS accounts for about 15% of children who enter
ESRF in Argentina (Table 2). Renal transplantation is
the preferred treatment modality for the disease asso-
ciated with SLT. Although some reports have described
recurrence in the graft [19], in large groups of children
with the postdiarrheal HUS, no recurrence has been doc-
umented [5, 20].
Three problems complicate an analysis of the risk of
recurrence of HUS in a transplanted kidney: (1) TMA
can be the pathologic pattern of acute immunologic re-
jection. (2) TMA has been seen in renal allografts in
patients receiving calcineurin inhibitors whose original
disease was not HUS and in patients with bone marrow or
liver transplantation. (3) Recurrence has been reported
predominantly in older children and adults, and in pa-
tients with familial, recurrent, or nonpostdiarrheal (D-)
forms of HUS.
In our own experience with transplantation after HUS,
only 1 patient lost his graft after 2 months. He was an 8-
year-old boy who had severe D- HUS, without recovering
from acute renal failure. Five years earlier, his brother
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Fig. 3. Actuarial survival of grafts in patients with HUS and without
HUS.
had had equally severe D-HUS. In reviewing the course
of 23 renal transplants in 20 children whose original dis-
ease had been HUS, 16 presented with the classic epi-
demic type, receiving 19 grafts. The survival of function-
ing grafts, maintenance of stable renal function, incidence
of acute rejection (AR), and prevalence of proteinuria
and hypertension were compared with the same variables
in a randomly selected group of 19 children who received
renal transplants because of ESRF not due to HUS. Mean
follow-up was 5 years, with a range of 1 to 11 years. Ac-
tuarial survival of grafts and of grafts with normal SCr
was similar in the 2 groups (P = 0.73 and 0.27, respec-
tively, log-rank test) (Figs. 3 and 4). Mean survival of the
grafts was 7.16 in the HUS group versus 8.53 years in the
controls (P = NS) (Fig. 3). Mean survival with normal
SCr was 2.07 in the HUS group versus 2.71 in the con-
trols (P = NS) (Fig. 4). There were 14 ARs in the HUS
group versus 8 ARs in the controls (P = NS). Prevalence
of proteinuria and hypertension at 1 and 5 years’ post-
transplantation was similar for both groups. No evidence
of TMA was seen in the 6 grafts biopsied for other indi-
cations [4]. In an extended review, including 25 patients
with classic HUS, there were no changes in the results of
the analysis (Table 3).
We conclude that patients who receive renal trans-
plants for classic epidemic HUS have a very low risk
of recurrence and that the long-term outcome of grafts
is not different from that in patients with ESRF from
other causes. Moreover, the use of calcineurin inhibitors
in these patients does not seem to increase the risk of
recurrence. Live related or cadaveric transplantation re-
mains the treatment of choice for children who had this
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Fig. 4. Actuarial survival of grafts with normal SCr (diagonal lines,
HUS; horizontal lines, non-HUS).
Table 3. Incidence of AR and prevalence of hypertension and
proteinuria
HUS Controls P value
AR 15 10 NS
Hypertension, first year 5/26 5/26 NS
Hypertension, fifth year 3/10 3/9 NS
Proteinuria, first year 7/26 6/26 NS
Proteinuria, fifth year 4/10 2/7 NS
Abbreviations are: AR, acute rejection, HUS, hemolytic uremic syndrome.
type of HUS. The most recent review of the literature
of the risk of recurrence found only 1 (0.8%) reported
recurrence in 118 children who had postdiarrheal HUS,
13 recurrences in 63 transplanted patients for D- HUS of
unknown mechanism, and 18 recurrences in those with
HUS associated with factor H deficiency, constitutional
deficiency of von Willebrand factor-cleaving protease, or
autosomal-dominant/recessive forms of HUS [20]. More
studies on the long-term course of these treatments and
the best time to use them are needed.
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